Got a Curzio spam the other day touting his newest CVA newsletter pick: And my newest pick could be the best-performing one of them all…It’s an under-the-radar biotech that recently applied for an FDA emergency use authorization. That’s when the government allows a healthcare product to be sold without having to go through the entire […]
↧
